相关实验视频

Updated: Jul 12, 2025

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

前列腺动脉栓塞作为症状良性前列腺增生症的治疗选择:立陶宛前性随访研究的结果

Tautvydas Jankauskas¹, Edgaras Buržinskis², Rytis Stasys Kaupas¹

¹Radiology Clinic, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.

Medicina (Kaunas, Lithuania)

|October 28, 2023

概括

前列腺动脉栓塞 (PAE) 为良性前列腺增生 (BPH) 提供了一种微创治疗方法. 这项研究发现,PAE在六个月内显著改善了尿路症状和前列腺指标,证明了它在缓解BPH症状方面的有效性.

科学领域:

泌尿器科泌尿器科泌尿器科泌尿器科
干预性放射学干预性放射学
男人的健康男人的健康

背景情况:

良性前列腺增生 (BPH) 是老年男性常见的疾病,导致下泌尿道症状.
前列腺动脉栓塞 (PAE) 是一种新兴的内血管治疗症状BPH.
通过诱导组织死,PAE旨在减少前列腺大小并改善阻塞性症状.

研究的目的:

评估PAE在缓解症状BPH的患者下尿路症状的有效性和疗效.
评估PAE对关键泌尿学参数和生活质量的影响.

主要方法:

一项针对70名患有症状BPH的男性进行的前性研究,这些男性在2019年至2022年期间接受了PAE.
泌尿学评估包括国际前列腺症状评分 (IPSS),生活质量 (QoL),国际勃起功能指数 (IIEF-5),尿道流量计 (Qmax),前列腺体积 (PV) 和空白后残留量 (PVR).
统计分析将基线测量与2个月和6个月后续数据进行了比较.

主要成果:

在PAE后,在手术后的2个月和6个月,在PV,Qmax,PVR,IPSS和QOL得分上观察到显著的改善.
平均前列腺体积下降,而Qmax和IPSS得分显著改善.
勃起功能 (IIEF-5) 没有显著变化,但其他BPH相关参数显示明显改善.

结论:

PAE是对症状性BPH的有希望的微创治疗方法,导致前列腺相关参数的显著改善.
这项研究强调了PAE在减轻尿道阻塞和缓解阻塞症状方面的有效性.
作为传统BPH治疗的有效替代品,PAE显示出相当大的潜力.

关键词:

年龄的年龄年龄的年龄.良性前列腺增大良性前列腺增大后续行动后续行动结果就是结果.前列腺动脉栓塞的前列腺动脉栓塞

更多相关视频

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...